Vendor Intelligence Report: Eternal Peptides

Published 3 Jul 2026. 24-page investigative report on who is behind Eternal Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 26 Finnrick lab tests, Eternal Peptides shows 9 pass / 17 fail — an overall pass rate of 35%. The result is not evenly distributed: Melanotan II is the cleanest tested signal and Retatrutide is the more defensible, but not clean, GLP choice, while BPC-157 is fail-heavy and Semaglutide has no passing Finnrick samples. Ratings also move under stricter fill-and-purity grading, making batch-level verification central.

The identity file is comparatively traceable but young. Site terms and New York records tie Eternal Peptides to Cenvira LLC, its DBA registration, and trademark applicants rather than an anonymous storefront. The chronology has a buyer-relevant gap: brand and entity signals start in 2024, while the current .com was captured for sale before becoming the active storefront.

Regulatory and channel risk are more about disruption and impersonation than pure anonymity. Eternal sells EP-coded GLP products under RUO language with lab-test mapping back to known compounds; it was not named in the April 2026 FDA warning-letter cluster, but the model overlaps the pattern. The submitted .net redirects to the .com, and a lookalike domain is treated as unaffiliated, yet no official channel registry was found.

Card processing is back online, a real improvement over nonreversible Zelle, CashApp and Bitcoin rails. The caution is governance and promotion: a prior lab-tests page exposed WordPress admin edit URLs, Janoshik COAs still require issuer verification, and the coupon ecosystem includes one disclosed affiliate plus undisclosed COUNTLESS code placements and a Finnrick-ranking claim contradicted by the data.

Inside the full report:

  • Complete Finnrick product-by-methodology breakdown and Appendix A lab table for all 5 tested products
  • NY DOS, DBA, trademark, and terms-page evidence tying the storefront to Cenvira LLC
  • Domain timeline from 2024 brand signals to the July 2025 for-sale .com capture and 2026 storefront
  • EP-to-GLP catalog-code mapping and FDA warning-letter pattern analysis for GLP/cagrilintide products
  • Payment-rail history, lookalike-channel checks, COA publishing-control finding, and affiliate-code scan

Risk assessment

  • Product-quality risk for specific tested peptides — high: BPC-157 is 2 pass / 7 fail at 35.96%; Semaglutide and Tirzepatide are each 0 pass / 4 fail; Melanotan II and Retatrutide are comparatively stronger.
  • Regulatory-disruption risk for GLP/cagrilintide catalog — high: EP-coded Semaglutide, Tirzepatide, Retatrutide and cagrilintide blends are sold RUO with reconstitution solution, matching the April 2026 FDA warning-letter enforcement pattern.
  • Affiliate-promotion risk — medium: A disclosed Peptide Critic affiliate and undisclosed COUNTLESS Reddit/Quora promo placements exist; a number-one Finnrick social claim is contradicted by Finnrick data.
  • Brand-confusion / unofficial-channel risk — medium: eternalpeptides.net redirects to eternalpeptides.com, but eternalpep.com and coupon/social placements create lookalike-channel confusion; no official-channel registry was located.